Out With the Old and In With the New, Again?

Slides:

Advertisements

Similar presentations

Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.

Advertisements

Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.

Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-I.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Phase 3 Treatment Naïve and Treatment Experienced Renal Disease

Compensated Cirrhosis

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.

David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.

The new Treatments The old problem Dr John F Dillon.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

Genotype 1 HCV infection Stable immunosuppressive therapy

ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1

Design No randomisation Open-label W12 W years HCV genotype 1

Design Randomisation 1 : 1 Open-label W16 W24 > 18 years

PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection

METAVIR F3-F4 criteria consensus

Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014

AL study: AL ODV + SMV in naïve patients, phase II

Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection

Phase 3 Treatment-Naïve and Treatment-Experienced

Initial Treatment of HCV G1 2016

ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.

QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3

Design W12 W16 Randomisation Open-label ≥ 18 years HCV genotype 1 or 4

L’inizio di una nuova era? University of Palermo, Italy

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

Resistance to Direct Acting Antiviral Therapy

Case 53-year-old Black Man

HCV Care in Unique Patient Populations

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

HCV Protease Inhibitors in Clinical Practice

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

Phase 3 Treatment-Naïve and Treatment-Experienced

Obiettivi e strategie di un

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

GS-US Study: SOF/VEL + GS in genotype 2, 3, 4 or 6 - Phase II

LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

A Guideline-Based Approach to HCV Care

HCV Protease Inhibitors in Clinical Practice

No HBV or HIV co-infection

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns

What Does the Future Hold and What Will It Mean for Patients?

Design W12 W16 Randomisation Open-label ≥ 18 years HCV genotype 1 or 4

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6

Presentation transcript:

Out With the Old and In With the New, Again?

Out With the Old, In With the New

Current Standard of Care

NEUTRINO and FISSION SOF + RBV ± pegIFN for Treatment-naive Patients

NEUTRINO and FISSION SOF + RBV ± pegIFN for Treatment-naive Patients

FUSION SOF + RBV ± pegIFN in Treatment-experienced Patients With G2,3 HCV

VALENCE SOF + RBV for 12 Weeks or 24 Weeks in G2 or G3 HCV Infection

QUEST 1 and 2 Q80K Variant Adversely Affects SVR12 of SMV-based Therapy

COSMOS SOF + SIM ± RBV for G1 HCV-infected Patients by Fibrosis Stage

2014 AASLD HCV Treatment Guidelines

ION-1 On the Road to IFN-free Therapy for G1 HCV Infection

ION-3 8 Weeks or 12 Weeks of SOF/LDV for Treatment-naive G1 HCV Infection

ION-2 SOF/LDV in G1 HCV-infected Patients Failing PegIFN/RBV ± DAA

HALLMARK-DUAL Phase 3 Trial of the All-oral Regimen DCV + ASV for G1b HCV Infection

SAPPHIRE I ABT-450/r/Ombitasvir + Dasabuvir (3D) + RBV for G1 HCV Infection

SAPPHIRE II ABT-450/r/Ombitasvir + Dasabuvir + RBV (3D) G1 HCV

TURQUOISE II ABT-450/r/Ombitasvir + Dasabuvir (3D) + RBV in Cirrhosis

The Past And Future of HCV Therapy

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)